Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
Research
[키워드] case sery
collected
conducted
Corticosteroid
Course
COVID-19
COVID-19 pandemic
determine
discharged
disease
Disease modifying therapy
enrolled
evaluated
expired
fatality
FIVE
Hospitalization
ICU admission
incidence
incidence rate
indicated
infected individual
Infection
information
Injections
Mild
moderate
MS
Multiple
multiple sclerosis
Neuromyelitis Optica
NMO
Occurrence
outcome
pandemic
Patient
patients died
patients treated
positive
Positive test
questionnaire
receiving
reported
required
Result
risk of COVID-19
rituximab
Safe
sclerosis
Self-isolation
severity
subject
Symptom
therapy
use of corticosteroid
[DOI] 10.1186/s12883-021-02218-4 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s12883-021-02218-4 PMC 바로가기 [Article Type] Research